Co-Founder and Chairman of the Board
Dr. Whisenant currently serves as the medical director for structural heart disease at Intermountain Health Care. His primary focus within the field of cardiology includes: Structural Heart Disease, Percutaneous Aortic Valve Replacement, Mitral Valve Repair, Mitral and Aortic Valvuloplasty, Left Atrial Appendage Closure, PFO and ASD Closure, High-Risk Coronary Intervention, and Percutaneous Mechanical Circulatory Support. Dr. Whisenant received his Doctor of Medicine from the Columbia University College of Physicians & Surgeons in 1992. His training included Internal Medicine residency from Harvard University from 1992-1995. He also trained as a fellow at UCSF Medical Center – San Francisco from 1995-1997, University of California – San Francisco, CA from 1997-1998, and Harvard University – Beth Israel Deaconess Medical Center – Boston, MA from 1998-1999. Dr. Whisenant is board certified in both Interventional Cardiology and Cardiovascular Disease. He is an active member of the American College of Cardiology & the American Medical Association.ALEX MARTIN
President & CEO, Coherex Medical
John Alexander (Alex) Martin joined Coherex Medical as Director, President and CEO in July 2012. Mr. Martin was most recently at WorldHeart Corporation as Director, President and CEO from February 2009 to April 2012. Previously, he was at Edwards Lifesciences where he was President of the North American Region and Corporate Vice President from June 2004 to July 2008.From 1999 to 2004 he was with Cordis Corporation, a Johnson and Johnson (J&J) company, where he served as Senior Vice President of International and prior to that, Vice President of Sales and Marketing. At Cordis, he had responsibility for all U.S. coronary therapeutic and diagnostic device sales and under his leadership the company experienced significant growth and became the market leader. Mr. Martin was responsible for the launch of the first commercialized drug-eluting stent in the US while at Cordis. Before Cordis, Mr. Martin served in sales, marketing and business development management positions at several organizations, including C.R. Bards’ USCI division, Cambridge Heart and IMED Corporation. He also served as Director of the Emergency Medical Services at The Medical Center at Bowling Green. Mr. Martin earned a bachelor’s degree from the University of Kentucky at Lexington.DANIEL COLE
Venture Partner, Oxford Bioscience
Dan Cole joined Oxford Bioscience Partners as a Venture Partner during 2009. He also serves as a General Partner of Spray Venture Partners, which he joined in 1996. Dan brings twenty years of medical device operational experience and has served on the Boards of 16 med-tech companies. Prior to joining Spray, Dan served as Senior Vice President and Group President of Boston Scientific Corporation’s vascular business, a $1.2 billion group including SCIMED (cardiology), Medi-tech (radiology), Meadox (vascular surgery), and EP Technologies (electrophysiology). He was also responsible for BSC’s rapidly growing international operations. Dan was previously President and Chief Operating Officer of SCIMED Life Systems, a public company with revenues of $260 million in 1994 prior to the company’s merger with Boston Scientific in 1995. He previously held a variety of executive and general management positions at Baxter Healthcare Divisions. He currently serves on the Board of Directors of IntraPace, Pathway Medical, superDimension, Tryton Medical, Direct Flow Medical, PneumRx, Conventus Orthopedics, and Thoratec Laboratories. He earned a B.S. in Aeronautical Engineering from the University of Kansas, an M.S. in Aeronautical Engineering from the United States Navy Post-Graduate School, and an M.B.A. from the University of California, Los Angeles.LISA DUNLEA
Signal Peak Venture Capital
Lisa has over 17 years of operating and investment experience in the medical device industry. She was previously a principal at Oxford Bioscience Partners in Boston and prior to Oxford Bioscience, she was with Spray Venture Partners. Lisa was the COO of Deep Vein Medical, a co-founder of Pulmonary Therapeutics and an integral part of founding MyoScience. She has experience launching and marketing new products on a worldwide basis, leading R&D efforts, conducting clinical trials for PMA, and establishing quality assurance systems. She has held management positions at The Cleveland Clinic Foundation and World Medical, acquired by Medtronic, and positions of increasing responsibility at Cordis Endovascular Systems, acquired by Johnson & Johnson, and General Electric Medical Systems. She represents Signal Peak on the boards of Aspen Avionics, Athena Feminine Technologies, LineaGen, nanoMR, Numira Biosciences, and VeraLight. Prior to the medical device industry she was an aerospace engineer at Pratt & Whitney. Lisa was a Kauffman Fellow, has an M.S. degree in Mechanical Engineering from Florida International University and an M.B.A from The Wharton School of Business.
Director, Volcano Corporation
Director, TomoTherapy, Inc.
Roy T. Tanaka,was appointed to the Board of Directors in April 2009. From 2004 through 2008, Mr. Tanaka served as the Worldwide President of Biosense Webster, Inc. for Johnson & Johnson. Mr. Tanaka joined Johnson & Johnson as the U.S. President of Biosense Webster, Inc. in 1997. From 1992 to 1997, he served in a variety of senior management positions at Sorin Biomedical, Inc., including President and Chief Executive Officer. From 1989 to 1992, Mr. Tanaka served in Vice President roles with Shiley, a division of Pfizer, Inc. Mr. Tanaka has been a director of Tomotherapy, Inc., a publicly traded medical device company, since 2008. Mr. Tanaka received a B.S. in Mechanical Engineering from Purdue University and an M.B.A. from Illinois Benedictine College.V. KADIR KADHIRESAN, PhD
Principal, Venture Investments, Johnson & Johnson Development Corporation
V. Kadir Kadhiresan, PhD, Principal, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2007. He serves on the boards of JJDC portfolio companies and is based in New Brunswick, New Jersey. Dr. Kadhiresan has more than a decade of operational experience in various functional roles including research, product development, and business development. Most recently as Director of Business Development at Guidant, Inc., now Boston Scientific, Inc., Dr. Kadhiresan led transactions in several novel medical device technologies for joint development, including mergers and acquisitions, and licensing and monetizing of nonstrategic assets. Prior to entering business development, he led the research and development of several early-stage technologies and managed more than 60 people. Dr. Kadhiresan was instrumental in the development of the cardiac resynchronization therapy for heart failure, a now $2+ billion worldwide market. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project. In addition, Dr. Kadhiresan is an inventor on more than 25 patents and has published several articles in peer-reviewed journals. Dr. Kadhiresan received a PhD and Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, and a Bachelor of Science in Electrical Engineering from REC, Trichy, India.Zack Scott
Director, Saints Capital
While at Saints Capital, Dr. Scott focuses on healthcare opportunities. Prior to joining Saints in 2008, Dr. Scott worked at Burrill & Co. where he made healthcare investments for nearly four years. Dr. Scott has invested in the areas of medical devices, health care services, diagnostics and biopharmaceuticals. Previously, Dr. Scott was a General Surgery resident at Oregon Health Science University in Portland, Oregon. Dr. Scott received an MBA and a certificate in Health Sector Management from the Fuqua School of Business at Duke University, where he was Fuqua Scholar. He received a BA in Economics from Duke University and an MD from the University of Texas Health Science Center at San Antonio. Dr. Scott is a member of the Alpha Omega Alpha Medical Honor Society.